Aclaris Therapeutics (ACRS) Equity Average: 2017-2025
Historic Equity Average for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $125.9 million.
- Aclaris Therapeutics' Equity Average fell 4.60% to $125.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.9 million, marking a year-over-year decrease of 4.60%. This contributed to the annual value of $156.4 million for FY2024, which is 11.86% down from last year.
- Aclaris Therapeutics' Equity Average amounted to $125.9 million in Q3 2025, which was down 8.69% from $137.9 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Equity Average peaked at $227.8 million during Q3 2022, and registered a low of $75.0 million during Q1 2021.
- Moreover, its 3-year median value for Equity Average was $149.6 million (2024), whereas its average is $151.5 million.
- Per our database at Business Quant, Aclaris Therapeutics' Equity Average skyrocketed by 427.91% in 2021 and then decreased by 26.23% in 2023.
- Over the past 5 years, Aclaris Therapeutics' Equity Average (Quarterly) stood at $207.0 million in 2021, then rose by 0.85% to $208.7 million in 2022, then decreased by 24.90% to $156.8 million in 2023, then fell by 8.87% to $142.9 million in 2024, then fell by 4.60% to $125.9 million in 2025.
- Its last three reported values are $125.9 million in Q3 2025, $137.9 million for Q2 2025, and $149.8 million during Q1 2025.